Schechter Investment Advisors LLC Sells 398 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Schechter Investment Advisors LLC reduced its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,843 shares of the medical equipment provider’s stock after selling 398 shares during the period. Schechter Investment Advisors LLC’s holdings in Zimmer Biomet were worth $468,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Tectonic Advisors LLC grew its position in Zimmer Biomet by 10.6% during the fourth quarter. Tectonic Advisors LLC now owns 2,091 shares of the medical equipment provider’s stock valued at $254,000 after acquiring an additional 201 shares during the last quarter. Pacer Advisors Inc. lifted its stake in Zimmer Biomet by 0.7% in the fourth quarter. Pacer Advisors Inc. now owns 16,734 shares of the medical equipment provider’s stock worth $2,037,000 after acquiring an additional 109 shares during the period. Raymond James Financial Services Advisors Inc. lifted its stake in Zimmer Biomet by 6.7% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 36,552 shares of the medical equipment provider’s stock worth $4,448,000 after acquiring an additional 2,298 shares during the period. Compagnie Lombard Odier SCmA lifted its stake in Zimmer Biomet by 441.9% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 2,330 shares of the medical equipment provider’s stock worth $284,000 after acquiring an additional 1,900 shares during the period. Finally, HB Wealth Management LLC lifted its stake in Zimmer Biomet by 30.0% in the fourth quarter. HB Wealth Management LLC now owns 3,357 shares of the medical equipment provider’s stock worth $409,000 after acquiring an additional 774 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ZBH. TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Raymond James raised their price objective on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Truist Financial raised their price objective on Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a research report on Friday, February 9th. JPMorgan Chase & Co. raised their price objective on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. Finally, Barclays raised their price target on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a report on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. According to MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average price target of $137.84.

Zimmer Biomet Stock Down 0.5 %

NYSE ZBH opened at $131.98 on Friday. The stock’s 50 day moving average is $125.46 and its 200 day moving average is $118.13. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25. The stock has a market cap of $27.07 billion, a PE ratio of 26.99, a P/E/G ratio of 2.44 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. During the same period in the previous year, the firm earned $1.88 EPS. The firm’s revenue was up 6.3% compared to the same quarter last year. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.73%. Zimmer Biomet’s dividend payout ratio (DPR) is 19.63%.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.95% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.